Patient and Physician Behavior
Our work in Patient and Physician Behavior
-
Association of Combination Statin and Antihypertensive Therapy With Reduced Alzheimer’s Disease and Related Dementia Risk
Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Categorized in -
Without Oversight, Electronic Prescribing Can Harm Patients
To protect patients from addiction, overdose, and even death, it may be necessary to rein in health information technology — or at least modify it.
Categorized in -
Helping Consumers Understand the Real Costs of Credit Cards
If consumers are to make informed choices about credit cards and other financial products, they need to understand how much these products cost them over time.
Categorized in -
A Checklist to Help Prevent and Manage Pressure Injury
The Federal Appropriations legislative package referenced a simple protocol to prevent and manage pressure injury developed by Bill Padula.
-
Potential Impacts of Recreational Marijuana Policies and Regulatory Structures that Could Reduce its Negative Impacts
Rosalie Liccardo Pacula presented before the Florida House of Representatives Health & Human Services Committee, Subcommittee on Health Quality on Dec. 11, 2019 about regulations to govern the use of recreational marijuana.
-
Does the Market Reward Quality?: Evidence from India
There are two salient facts about health care in low and middle-income countries; 1) the private sector plays an important role and 2) the care provided is often of poor quality.
Categorized in -
Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in -
Treatments for the Leading Cause of Blindness in the US Generate $0.9 to $3 Billion for Society, According to New Economic Analysis
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in -
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Research by Jakub Hlavka and colleagues suggests a combination of brief cognitive tests and blood-based biomarker tests will allow primary care physicians to identify patients with potential early stage Alzheimer’s disease efficiently and triage them for further evaluation.
Categorized in -
Extended-Release Formulation and Medication Adherence
Suboptimal adherence to chronic medications undermines treatment effectiveness and costs the U.S. as much as $289 billion annually. This is the first study to analyze the impact of extended-release formulations on long-term adherence.
Categorized in